Table 3. Cross Sectional Association Between Baseline Lumbar Spine Bone Mineral Density (LS BMD) and Prevalent Vertebral Deformity Adjusted for Age, Body Mass Index, Race, Baseline LS BMD and Menopause Transition Stage, the Study of Women’s Health Across the Nation (N = 823).
| Characteristic | Odds Ratios of Vertebral Deformity (95% Confidence Interval) | p-value |
|---|---|---|
| LS BMD1 | 1.61 (1.07, 2.44) | 0.024 |
| Race2 | 0.840 | |
| Black | 0.67 (0.25, 1.81) | |
| Chinese | 1.03 (0.34, 3.16) | |
| Japanese | 1.15 (0.41, 3.24) | |
| Menopause Transition Stage3 | 0.247 | |
| Late Perimenopause | 0.60 (0.17, 2.12) | |
| Natural Postmenopause | 0.36 (0.13, 1.01) | |
| Surgical Postmenopause | 0.21 (0.12, 3.69) | |
| Body Mass Index4 (kg/m2) | 1.04 (0.99, 1.10) | 0.116 |
| Age (years) | 1.21 (1.03, 1.41) | 0.022 |
1Odds of vertebral deformity are expressed per one standard deviation decrement in LS BMD; BMD was measured at SWAN study baseline. Among women who were never users of bone-active medications, mean LS BMD was 1.08g/cm2 (standard deviation,0.13)
2White race is referent.
3Referent group was premenopausal or early menopausal menopause transition stage; see Methods for definitions of menopause stages.
4Odds of vertebral deformity are expressed per one standard deviation unit of body mass index (BMI). Among women not using bone-active medications, mean BMI was 28.5 kg/m2 (standard deviation, 7.0).